Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories

Abstract

Background and Purpose Three network laboratories measured antibodies to islet autoantigens. Antibodies to glutamic acid decarboxylase (GAD65 [GADA]) and the intracellular portion of protein tyrosine phosphatase (IA-2ic [IA-2A]) were measured by similar, but not identical, methods in samples from participants in the Type 1 Diabetes Genetics Consortium (T1DGC).

Methods All laboratories used radiobinding assays to detect antibodies to in vitro transcribed and translated antigen, but with different local standards, calibrated against the World Health Organization (WHO) reference reagent. Using a common method to calculate WHO units/mL, we compared results reported on samples included in the Diabetes Autoantibody Standardization Program (DASP), and developed standard methods for reporting in WHO units/mL. We evaluated intra-assay and inter-assay coefficient of variation (CV) in blind duplicate samples and assay comparability in four DASP workshops.

Results Values were linearly related in the three laboratories for both GADA and IA-2A, and intra-assay technical errors for values within the standard curve were below 13% for GADA and below 8.5% for IA-2A. Correlations in samples tested 1—2 years apart were >97%. Over the course of the study, internal CVs were 10—20% with one exception, and the laboratories concordantly called samples GADA or IA-2A positive or negative in 96.7% and 99.6% of duplicates within the standard curve. Despite acceptable CVs and general concordance in ranking samples, the laboratories differed markedly in absolute values for GADA and IA-2A reported in WHO units/mL in DASP over a large range of values.

Limitations With three laboratories using different assay methods (including calibrators), consistent values among them could not be attained.

Conclusions Modifications in the assays are needed to improve comparability of results expressed as WHO units/mL across laboratories. It will be essential to retain high intra- and inter-assay precision, sensitivity and specificity and to confirm the accuracy of harmonized methods. Clinical Trials 2010; 7: S56—S64. http:// ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

Baekkeskov S.

Aanstoot HJ

Christgau S.

, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as GABA-synthesizing enzyme glutamic acid decarboxylase . Nature (London)1990; 347: 151-56.

Rabin DU

Pleasic SM

Shapiro JA

, et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol1994; 152: 3183-88.

Lan SM

Lu J.

Goto Y.

Notkins AJ

Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol1994; 13: 505-14.

Payton MA

Hawkes CJ

Christie MR

Relationship of the 37,000- and the 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest1995 ; 96: 1506-11.

Bonifacio E.

Genovese S.

Braghi S.

, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia1995; 38: 816-22.

Bingley PJ

Bonifacio E.

Mueller PW

Diabetes Antibody Standardization Program: first assay proficiency evaluation . Diabetes2003; 52: 1128-36.

Torn C.

Mueller PW

Schlosser M.

, et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia2008; 51: 846-52.

Verge CF

Stenger D.

Bonifacio E.

, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes1998; 47: 1857-66.

Bingley PJ

Bonifacio E.

Williams AJ

, et al. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes1997; 46: 1701-10.

10.

Colman PG

McNair P.

Margetts H.

, et al. The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. Med J Aust1998; 169: 81-84.

11.

Mire-Sluis AR

Gaines Das R.

Lernmark A.

Participants of the study. The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia2000; 43: 1282-92.